Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.
Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.
Affiliation: BresMed, Sheffield, UK.Show MeSH
Related in: MedlinePlus
Mentions: A probabilistic sensitivity analysis (PSA) was also performed, producing 100 pairs of incremental effectiveness and cost results. These were plotted on a cost-effectiveness plane to illustrate the probability of being cost-effective for both countries’ willingness-to-pay (WTP) thresholds (figure 3).